Simple Drug Change Could Save Medicare Hundreds of Millions
Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...
Australia’s regulatory agency rejected Biogen and Eisai’s Alzheimer’s drug Leqembi, noting that the drug's efficacy doesn't ...
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
The number of U.S. children who suffer seizures after swallowing prescription medications or illicit drugs has doubled in ...
About 6% of Leqembi (lecanemab) is discarded because patients are frequently prescribed doses lower than the size of the drug’s single-use vials. This waste costs Medicare about $1,600 a patient ...
In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...
“We might be able to have a big impact.” Since January 2023, two new drug treatments — Leqembi made by Eisai and Biogen and Kisunla made by Eli Lilly — have been approved by the Food and ...
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback